The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
Medical Device Network on MSN4d
Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenueDexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...
BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA.
The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust CAGR of 27.5%, reaching ...
The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust ...
Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback